India, July 24 -- Alumis Inc. (ALMS) has completed patient enrollment in its global phase IIb trial of ESK-001 for the treatment of systemic lupus erythematosus, the most common form of lupus.
The phase IIb trial, dubbed LUMUS, has enrolled 408 patients who are receiving ESK-001 or a placebo for 48 weeks. The primary endpoint will be to assess improvements in overall disease activity using the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Week 48.
Lupus occurs when the immune system attacks its tissues, causing inflammation, and in some cases, permanent tissue damage, which can be widespread, affecting many parts of the body, like the skin, joints, heart, lungs, kidneys, circulating blood cells, and brai...